Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cells

Author(s): Xiao Guo, Qin Li, Yan-Fang Wang, Tian-Yun Wang*, Si-Jia Chen, Zheng-Wei Tian

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 13 , Issue 2 , 2018

Become EABM
Become Reviewer
Call for Editor


Background: Vincristine (VCR) resistance can lead to cancer chemotherapy failure. Although changes in gene expression are responsible for drug resistance, the specific identities and roles of these genes remain unclear.

Objective: In this study, we aimed to identify differentially expressed genes and mechanisms of VCR resistance in colorectal cancer (CRC) cells.

Methods: A VCR-resistant CRC cell line (HCT-8/VCR) was established, and differentially expressed proteins between HCT-8 and HCT-8/VCR cells were screened using a human cytokine array; the results were confirmed by reverse transcription polymerase chain reaction and Western blotting. Furthermore, differentially expressed proteins were downregulated using siRNA, and cell proliferation and apoptosis were assessed by Cell Counting Kit-8 assay and flow cytometry, respectively.

Results: Compared with HCT-8 CRC cells, HCT-8/VCR cells showed downregulation of lipocalin 2 (LCN2). We found that siRNA-mediated downregulation of LCN2 in HCT-8 cells significantly increased VCR resistance. Furthermore, when we downregulated LCN2, we observed significant decreases in apoptosis, but no significant effect on cell cycle.

Conclusion: Overall, these results demonstrate that LCN2 plays an important role in VCR resistance and is a potential therapeutic target for this disease.

Keywords: Colon cancer, cell cycle, lipocalin 2, therapeutic target, vincristin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 11 May, 2018
Page: [248 - 254]
Pages: 7
DOI: 10.2174/1574892813666171221120504
Price: $65

Article Metrics

PDF: 46
PRC: 2